The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | VenBd shows significant improvement in PFS for R/R MM
Shaji Kumar, MD, Mayo Clinic, Rochester, MN, discusses the BELLINI trial (NCT02755597). The study evaluated the combination of venetoclax with bortezomib and dexamethasone (VenBd) in patients with relapsed/refractory multiple myeloma who received 1-3 prior therapies. Updated results continue to show significant improvement in progression-free survival, although the difference in overall survival is no longer significant. Dr Kumar reveals that a biomarker-based approach might be necessary for the selection of patients most likely to respond to venetoclax-based treatments. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
